Loading...
NASDAQ: MRNA
Moderna, Inc.
Healthcare · Biotechnology
●S&P 500 since 2021
Market Cap
$20.69B
52w High
$59.55
52w Low
$22.28
P/E
-7.28
Volume
6.44M
Outstanding Shares
394.94M
Company profile
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally.
CEOStéphane Bancel
SectorHealthcare
IndustryBiotechnology
Employees5,800
IPO dateDec 7, 2018
Valuation
Forward P/E—
EV/EBITDA-4.23
Enterprise value$10.79B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth-29.08%
Gross margin14.1%▲2.05%vs FY2024
Operating margin-158.21%▼28.23%vs FY2024
ROE-32.62%▲0.13%vs FY2024
Analyst consensus
RatingHold
Target price$35.67▼31.93%
8
Buy
15
Hold
4
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
View
EPS
Actual vs estimate by quarter
Q2FY25
ActualEst.
-$2.13
-$2.99
Q3FY25
ActualEst.
-$0.51
-$1.87
Q4FY25
ActualEst.
-$2.11
-$2.54
Q1FY26
Next Est.
—
Revenue
Actual vs estimate by quarter
Q2FY25
ActualEst.
$142M
$893.29M
Q3FY25
ActualEst.
$1.02B
$920.86M
Q4FY25
ActualEst.
$678M
$635.15M
Q1FY26
Next Est.
—